Elo Mutual Pension Insurance Co Purchases 9,411 Shares of Exelixis, Inc. $EXEL

Elo Mutual Pension Insurance Co boosted its position in Exelixis, Inc. (NASDAQ:EXEL) by 62.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,364 shares of the biotechnology company’s stock after purchasing an additional 9,411 shares during the quarter. Elo Mutual Pension Insurance Co’s holdings in Exelixis were worth $1,074,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently made changes to their positions in EXEL. Avantax Advisory Services Inc. purchased a new stake in shares of Exelixis in the first quarter worth $551,000. Cetera Investment Advisers increased its stake in Exelixis by 1.6% in the 1st quarter. Cetera Investment Advisers now owns 118,599 shares of the biotechnology company’s stock worth $4,379,000 after acquiring an additional 1,925 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Exelixis by 3.9% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 65,913 shares of the biotechnology company’s stock valued at $2,434,000 after acquiring an additional 2,466 shares during the last quarter. LPL Financial LLC boosted its position in shares of Exelixis by 74.5% during the 1st quarter. LPL Financial LLC now owns 187,097 shares of the biotechnology company’s stock valued at $6,908,000 after acquiring an additional 79,885 shares during the last quarter. Finally, Federated Hermes Inc. increased its position in shares of Exelixis by 18.3% in the first quarter. Federated Hermes Inc. now owns 483,738 shares of the biotechnology company’s stock worth $17,860,000 after purchasing an additional 74,806 shares during the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on EXEL shares. Wall Street Zen upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. HC Wainwright raised their price objective on shares of Exelixis from $46.00 to $49.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Stifel Nicolaus set a $43.00 target price on shares of Exelixis in a research report on Wednesday, November 5th. Barclays raised their price target on Exelixis from $40.00 to $41.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 5th. Finally, UBS Group raised their price objective on Exelixis from $35.00 to $40.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and twelve have issued a Hold rating to the company’s stock. According to data from MarketBeat, Exelixis currently has a consensus rating of “Moderate Buy” and an average target price of $45.45.

Exelixis Trading Down 0.2%

NASDAQ EXEL opened at $44.12 on Friday. The firm has a market cap of $11.83 billion, a PE ratio of 21.21, a price-to-earnings-growth ratio of 0.79 and a beta of 0.32. Exelixis, Inc. has a 1-year low of $31.90 and a 1-year high of $49.62. The stock has a 50-day moving average of $40.24 and a 200-day moving average of $40.87.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.10. The company had revenue of $597.76 million during the quarter, compared to analysts’ expectations of $590.04 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.Exelixis’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.47 EPS. Exelixis has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Dana Aftab sold 48,383 shares of the company’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $42.50, for a total transaction of $2,056,277.50. Following the completion of the sale, the executive vice president directly owned 664,778 shares in the company, valued at $28,253,065. This represents a 6.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Mary C. Beckerle sold 24,622 shares of the firm’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $41.93, for a total transaction of $1,032,400.46. Following the completion of the sale, the director directly owned 21,380 shares in the company, valued at approximately $896,463.40. This trade represents a 53.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 245,235 shares of company stock valued at $10,490,600 in the last three months. Corporate insiders own 2.82% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.